DE69428130T2 - Verwendung von bcl-2 zur herstellung von arzneimitteln zur therapeutischen behandlung und verhinderung von krankheiten - Google Patents

Verwendung von bcl-2 zur herstellung von arzneimitteln zur therapeutischen behandlung und verhinderung von krankheiten

Info

Publication number
DE69428130T2
DE69428130T2 DE69428130T DE69428130T DE69428130T2 DE 69428130 T2 DE69428130 T2 DE 69428130T2 DE 69428130 T DE69428130 T DE 69428130T DE 69428130 T DE69428130 T DE 69428130T DE 69428130 T2 DE69428130 T2 DE 69428130T2
Authority
DE
Germany
Prior art keywords
bcl
diseases
prevention
therapeutic treatment
medicinal products
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69428130T
Other languages
English (en)
Other versions
DE69428130D1 (de
DE69428130T3 (de
Inventor
John C Reed
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
JOLLA CANCER RES FOUNDATION LA
La Jolla Cancer Research Foundation
Original Assignee
JOLLA CANCER RES FOUNDATION LA
La Jolla Cancer Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22070248&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69428130(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by JOLLA CANCER RES FOUNDATION LA, La Jolla Cancer Research Foundation filed Critical JOLLA CANCER RES FOUNDATION LA
Publication of DE69428130D1 publication Critical patent/DE69428130D1/de
Publication of DE69428130T2 publication Critical patent/DE69428130T2/de
Application granted granted Critical
Publication of DE69428130T3 publication Critical patent/DE69428130T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/02—Animal zootechnically ameliorated
    • A01K2267/025—Animal producing cells or organs for transplantation
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0318—Animal model for neurodegenerative disease, e.g. non- Alzheimer's
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Environmental Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Husbandry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
DE69428130T 1993-05-26 1994-05-26 Verwendung von bcl-2 zur herstellung von arzneimitteln zur therapeutischen behandlung und verhinderung von krankheiten Expired - Lifetime DE69428130T3 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/066,556 US5550019A (en) 1993-05-26 1993-05-26 Methods of identifying compounds which alter apoptosis
US66556 1993-05-26
PCT/US1994/005980 WO1994027426A1 (en) 1993-05-26 1994-05-26 Methods of using bcl-2 for the therapeutic treatment and prevention of diseases

Publications (3)

Publication Number Publication Date
DE69428130D1 DE69428130D1 (de) 2001-10-04
DE69428130T2 true DE69428130T2 (de) 2002-05-02
DE69428130T3 DE69428130T3 (de) 2006-10-12

Family

ID=22070248

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69428130T Expired - Lifetime DE69428130T3 (de) 1993-05-26 1994-05-26 Verwendung von bcl-2 zur herstellung von arzneimitteln zur therapeutischen behandlung und verhinderung von krankheiten

Country Status (10)

Country Link
US (4) US5550019A (de)
EP (2) EP1130087A3 (de)
JP (2) JP3704348B2 (de)
AT (1) ATE204704T1 (de)
CA (1) CA2163439C (de)
DE (1) DE69428130T3 (de)
DK (1) DK0751709T3 (de)
ES (1) ES2160124T3 (de)
PT (1) PT751709E (de)
WO (1) WO1994027426A1 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5831066A (en) * 1988-12-22 1998-11-03 The Trustees Of The University Of Pennsylvania Regulation of bcl-2 gene expression
US6841541B1 (en) 1992-02-21 2005-01-11 The Trustees Of The University Of Pennsylvania Regulation of BCL-2-gene expression
US5539085A (en) * 1993-08-20 1996-07-23 Onyx Pharmaceuticals, Inc. Bcl-2 and R-ras complex
US6231852B1 (en) 1993-11-18 2001-05-15 The Regents Of The University Of California Method for reducing BCL-2 expressing cells resistance to death
FR2739561B1 (fr) * 1995-10-06 1997-12-26 Inst Nat Sante Rech Med Utilisation d'un vecteur assurant l'expression ou l'augmentation transitoire de l'activite bc1-2
US5972622A (en) * 1996-02-08 1999-10-26 Desjardins; Louise Method of detecting apoptosis using an anti-human GP46 monoclonal anti-body
US5744460A (en) * 1996-03-07 1998-04-28 Novartis Corporation Combination for treatment of proliferative diseases
AUPN896596A0 (en) * 1996-03-27 1996-04-26 Walter And Eliza Hall Institute Of Medical Research, The Therapeutic molecules
JP2000515137A (ja) * 1996-07-12 2000-11-14 マサチューセッツ インスティチュート オブ テクノロジー 軸索の成長を制御する方法
CA2260766A1 (en) * 1996-07-12 1998-01-22 Emory University Regulation of apoptosis and in vitro model for studies thereof
US6558900B2 (en) 1996-07-12 2003-05-06 Emory University Regulation of apoptosis and in vitro model for studies thereof
US6180402B1 (en) 1996-11-20 2001-01-30 Qlt Inc. Method for inhibiting apoptosis induced by photodynamic therapy using a cysteine or serine protease inhibitor
WO1998044142A1 (en) 1997-04-01 1998-10-08 The General Hospital Corporation Molecular marker for muscle stem cells
US6720311B2 (en) 1997-12-18 2004-04-13 David Tsai Polypeptide for the treatment of cancer and a method for preparation thereof
US6737402B2 (en) 1997-12-18 2004-05-18 David Tsai Method of preparing fetuin to induce apoptosis
US7238662B2 (en) * 1997-12-18 2007-07-03 Ambryx Biotechnology, Inc. Alpha 2HS glycoprotein for treatment of cancer and a method for preparation thereof
US20010041342A1 (en) * 1998-04-01 2001-11-15 The General Hospital Corporation, A Massachusetts Corporation Molecular marker for muscle stem cells
US7381413B1 (en) * 1998-04-17 2008-06-03 University Of Vermont And State Agricultural College Methods and products related to metabolic interactions in disease
CA2343746A1 (en) * 1998-07-10 2000-01-20 Meiji Milk Products Co., Ltd. Therapeutic agents for apoptosis-related diseases
US7951544B1 (en) 1999-07-09 2011-05-31 Sanford-Burnham Medical Research Institute Method for determining the prognosis of cancer patients by measuring levels of bag expression
US6277974B1 (en) * 1999-12-14 2001-08-21 Cogent Neuroscience, Inc. Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
WO2001052639A1 (en) 2000-01-21 2001-07-26 Beth Israel Deaconess Medical Center Use of pro-apoptotic factors in treatment of atherosclerosis
US6773894B1 (en) * 2000-01-21 2004-08-10 Biochain Institute, Inc. Isolation and extraction of subcellularly compartmentalized protein
US20030044413A1 (en) * 2000-08-15 2003-03-06 Regents Of The University Of Minnesota Methods of limiting apoptosis of cells
US7795232B1 (en) 2000-08-25 2010-09-14 Genta Incorporated Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
DE60230774D1 (de) * 2001-04-20 2009-02-26 Children S Hospital Of Orange Isolierung von nervenstammzellen unter verwendung von gangliosiden und anderen oberflächenmarkern
DE10228187A1 (de) * 2002-06-24 2004-01-22 MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH Testsystem zum Nachweis von Krebserkrankungen
US8017323B2 (en) * 2003-03-26 2011-09-13 President And Fellows Of Harvard College Free reactant use in nucleic acid-templated synthesis
WO2005014017A1 (ja) 2003-08-08 2005-02-17 Yuji Shino 癌治療用医薬組成物
JP2005305107A (ja) * 2004-03-25 2005-11-04 Sei Matsuoka 価値的情報値の測定装置およびこれを使用した測定方法
US7531327B2 (en) * 2004-07-23 2009-05-12 Immunomedics, Inc. Methods and compositions for increasing longevity and protein yield from a cell culture
US7537930B2 (en) 2004-07-23 2009-05-26 Immunomedics, Inc. Mammalian cell lines for increasing longevity and protein yield from a cell culture
US7608425B2 (en) * 2004-07-23 2009-10-27 Immunomedics, Inc. Methods for protein expression in mammalian cells in serum-free medium
US20060159681A1 (en) * 2004-12-14 2006-07-20 Functional Neuroscience Inc. Compositions and methods to inhibit cell loss by using inhibitors of BAG
US20070092947A1 (en) * 2005-10-20 2007-04-26 Immunomedics, Inc. Methods and compositions for increasing longevity and protein yield from a cell culture
DK2540820T3 (en) 2005-12-09 2018-03-12 Academisch Medisch Centrum Bij De Univ Van Amsterdam METHODS AND PROCEDURES FOR AFFECTING THE STABILITY OF ANTIBODY-PRODUCING CELLS
WO2007067032A1 (en) 2005-12-09 2007-06-14 Academisch Medisch Cemtrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of cells
ITMI20060384A1 (it) * 2006-03-03 2007-09-04 Umberto Cornelli Composizioni comprendenti chitosano atte al trattamento terapeutico complessivo o alla prevenzione complessiva della sindrome metabolica
US20100189802A1 (en) * 2007-08-21 2010-07-29 Scott And White Memorial Hospital And Scott, Sherwood, And Brindley Foundation Method for treatment of vascular hyperpermeability
US20090069223A1 (en) * 2007-08-21 2009-03-12 Childs Ed W Method for treatment of vascular hyperpermeability
US8192420B2 (en) 2007-12-20 2012-06-05 Acclarent, Inc. Iontophoresis methods
WO2009122580A1 (ja) * 2008-04-03 2009-10-08 株式会社ツムラ 抑肝散のバイオアッセイ方法
US20110136231A1 (en) 2008-04-11 2011-06-09 Cytotech Labs, Llc Methods and use of inducing apoptosis in cancer cells
US20110059191A1 (en) * 2008-05-23 2011-03-10 Nishihara Co., Ltd. Bcl-2 protein expressing agent, apoptosis inhibiting agent and agent for preventing ultraviolet dna damage of epidermal cell
AU2010271583B2 (en) 2009-07-15 2015-02-12 Kling Biotherapeutics B.V. Means and methods for producing high affinity antibodies
PL2646466T3 (pl) 2010-12-02 2017-09-29 Aimm Therapeutics B.V. Środki i sposoby do wytwarzania przeciwciał o wysokim powinowactwie
US20130190678A1 (en) 2011-07-25 2013-07-25 Bernard H. Andreas Personalizable system and method for anesthetizing the tympanic membrane
US10611829B2 (en) 2014-01-31 2020-04-07 Aimm Therapeutics B.V. Means and methods for producing stable antibodies
US10016304B2 (en) 2015-07-16 2018-07-10 Tusker Medical, Inc. Earplug assembly for iontophoresis system
WO2020219504A1 (en) * 2019-04-23 2020-10-29 The Regents Of The University Of California Modulating survival of therapeutic cells and methods, cells and nucleic acids related thereto
KR20240070523A (ko) * 2021-08-11 2024-05-21 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 키메라 항원 수용체 암 면역요법 효능을 증강시키기 위한 Bcl-2의 조절

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4271145A (en) * 1979-10-22 1981-06-02 The Massachusetts General Hospital Process for producing antibodies to hepatitis virus and cell lines therefor
US5202429A (en) * 1986-07-09 1993-04-13 The Wistar Institute DNA molecules having human BCL-2 gene sequences
US4997764A (en) 1987-04-23 1991-03-05 New York University Transformation of human B-lympocytes with Epstein Barr virus and c-myc containing vectors
US5024947A (en) 1987-07-24 1991-06-18 Cetus Corporation Serum free media for the growth on insect cells and expression of products thereby
US5149628A (en) * 1989-11-15 1992-09-22 Temple University Methods for detecting bcl-3 gene in human leukemias
US5328844A (en) 1990-05-09 1994-07-12 University Of Colorado Foundation, Inc. Culture media for mammalian cells
WO1992022640A1 (en) * 1991-06-10 1992-12-23 Research Development Foundation Rb TRANSFERRED CELLS AND METHOD
EP0633934A1 (de) * 1992-04-02 1995-01-18 Imperial Cancer Research Technology Limited Modifizierte Zellen und Behandlungsverfahren

Also Published As

Publication number Publication date
EP0751709A1 (de) 1997-01-08
JP3867033B2 (ja) 2007-01-10
ATE204704T1 (de) 2001-09-15
EP0751709A4 (de) 1997-09-24
EP0751709B1 (de) 2001-08-29
CA2163439C (en) 2011-01-04
EP1130087A2 (de) 2001-09-05
CA2163439A1 (en) 1994-12-08
US5550019A (en) 1996-08-27
EP0751709B2 (de) 2006-03-29
JP2003176236A (ja) 2003-06-24
US20030069201A1 (en) 2003-04-10
JPH09502083A (ja) 1997-03-04
WO1994027426A1 (en) 1994-12-08
PT751709E (pt) 2001-12-28
US20080102060A1 (en) 2008-05-01
ES2160124T3 (es) 2001-11-01
US7910370B2 (en) 2011-03-22
DE69428130D1 (de) 2001-10-04
JP3704348B2 (ja) 2005-10-12
US6514761B1 (en) 2003-02-04
DE69428130T3 (de) 2006-10-12
US7427495B2 (en) 2008-09-23
DK0751709T3 (da) 2002-03-04
EP1130087A3 (de) 2003-10-29

Similar Documents

Publication Publication Date Title
DE69428130T2 (de) Verwendung von bcl-2 zur herstellung von arzneimitteln zur therapeutischen behandlung und verhinderung von krankheiten
DE69124293D1 (de) Vorrichtung zur Behandlung von Wirbelsäulenerkrankungen
DE69331605T2 (de) Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen
ATE275383T1 (de) Oxadisäuren und verwandte verbindungen zur behandlung von hautstörungen
ATE116848T1 (de) Verwendung von baclofen zur herstellung von arzneimitteln zur behandlung von angina pectoris.
DE69121561D1 (de) Verwendung von 3-guanidinopropionsäure zur herstellung eines medikaments zur behandlung und prävention von fettsucht
DE69713620D1 (de) Verwendung von arachidonsäure und/oder docohexaensäure zur herstellung eines arzneimittels zur behandlung von dyspraxia
DE69011951T2 (de) Verfahren zur Behandlung und Herstellung von Material.
ATE269077T1 (de) Verwendung von tetrahydropyridinderivaten zur herstellung von arzneimitteln zur behandlung demyelinisierender erkrankungen
DE69532066D1 (de) Arzneimittel zur Behandlung von Restenosis und Gefässsklerose
DE69431199D1 (de) Melatonin-Derivate zur Verwendung in der Behandlung von Schlafstörungen
ATE239470T1 (de) Melatonin-derivate zur verwendung in der behandlung von desynchronisierungs-erkankungen
ATE135220T1 (de) Verwendung von 1-alpha,24(r)-dihydroxy-22(e)- dehydrovitamin-d3 zur herstellung eines arzneimittels zur behandlung der osteoporose
DE69424563T2 (de) Verwendung von dimeticon zur herstellung eines arzneimittels zur behandlung von aphthen und stomatitis
DE69026511T2 (de) Verwendung von gibberellinen zur herstellung eines arzneimittels zur behandlung von prostatitis
DE29620182U1 (de) Humantherapeutisches Erzeugnis zur Behandlung und/oder Vorbeugung von Krankheiten durch Dämpfe von ätherischen Ölen
DE59309732D1 (de) Arzneimittel zur behandlung und prophylaxe von knochen- und gelenkserkrankungen
ATE319472T1 (de) Verfahren zur behandlung der gefässerkrankungen mit aktiviertem protein c
DE3784738T2 (de) Topische vorstufen von arzneimitteln zur behandlung von akne und hautkrankheiten.
DE69121999D1 (de) Verfahren und Produkt für die Behandlung von Magenkrankheiten
DE69424415D1 (de) Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung parkinsonscher krankheit
ATE263565T1 (de) Verwendung von 8,9-dehydroestron zur herstellung eines arzneimittels zur behandlung von durch freie radikale verursachte krankheiten
ATE186640T1 (de) Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung neurogenerativer erkrankungen
ATA14996A (de) Verwendung von galanthamin zum herstellen von arzneimitteln zur behandlung von trisomie 21 oder verwandter trisomie-syndrome
DE69426622T2 (de) Verwendung von triazinverbindungen zur herstellung eines arzneimittels zur behandlung von erinnerungs-und lernstörungen

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings